Advanced therapy medicinal products (ATMPs), which include gene therapy medicinal products, somatic cell therapy medicinal products and tissue-engineered products, are at the cutting edge of innovation and offer a major hope for various diseases for which there are limited or no therapeutic options. They have therefore been subject to considerable interest and debate. Following the European regulation on ATMPs, a consolidated regulatory framework for these innovative medicines has recently been established. Central to this framework is the Committee for Advanced Therapies (CAT) at the European Medicines Agency (EMA), comprising a multidisciplinary scientific expert committee, representing all EU member states and European Free Trade Association countries, as well as patient and medical associations. In this article, the CAT discusses some of the typical issues raised by developers of ATMPs, and highlights the opportunities for such companies and research groups to approach the EMA and the CAT as a regulatory advisor during development.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
The European Parliament and the Council of the European Union. Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. Official J. Eur. Union 10.12.2007, L324/121–L324/137 (2007).
The European Parliament and the Council of the European Union. Commission Directive 2009/120/EC of 14 September 2009 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use as regards advanced therapy medicinal products. Official J. Europ. Union 15.9.2009, L242/3–L242/12 (2009).
Aiuti, A. et al. Gene therapy for immunodeficiency due to adenosine deaminase deficienty. N. Engl. J. Med. 360, 447–458 (2009).
Kohn, D. B. & Candotti, F. Gene therapy fulfilling its promise. N. Engl. J. Med. 360, 518–521 (2009).
Bainbridge, J. W. et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 358, 2231–2239 (2009).
Baum, C., Kustikova, O., Modlich, U., Li, Z. & Fehse, B. Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum. Gene Ther. 17, 253–263 (2006).
Couzin, J. & Kaiser, J. Gene therapy. As Gelsinger case ends, gene therapy suffers another blow. Science 307,1028 (2005).
Amariglio, N. et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med. 6, e1000029 (2009).
Getgood, A., Brooks, R., Fortier, L. & Rushton, N. Articular cartilage tissue engineering. J. Bone Joint Surg. 91B, 565–575 (2009).
MacNeil, S. Progress and opportunities for tissue-engineered skin. Nature 445, 874–880 (2007).
Nishikawa, S., Goldstein, R. A. & Nierras, C. R. The promise of human induced pluripotent stem cells for research and therapy. Nature Rev. Mol. Cell Biol. 9, 725–729 (2008).
European Medicines Agency. Guideline on safety and efficacy follow-up — risk management of advanced therapy medicinal products EMEA/149995/2008. EMA website [online], (2008).
Hoos, A. et al.: A clinical development paradigm for cancer vaccines and related biologics. J. Immunother. 30, 1–15 (2007).
European Medicines Agency. Guideline on human cell-based medicinal products EMEA/CHMP/410869/2006. EMA web site [online], (2008).
Somia, N. & Verma, I. M. Gene therapy: trials and tribulations. Nature Rev. Genet. 1, 91–99 (2000).
Broussau, S. et al. Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture. Mol. Ther. 16, 500–507 (2008).
Aslanidi, G., Lamb, K. & Zolotukhin, S. An inducible system for highly efficient production of recombinant adeno-associated virus (rAAV) vectors in insect Sf9 cells. Proc. Natl Acad. Sci. USA 106, 5059–5064 (2009).
Wilson, C. A. & Cichutek, K. The US and EU regulatory perspectives on the clinical use of hematopoietic stem/progenitor cells genetically modified ex vivo by retroviral vectors. Methods Mol. Biol. 506, 477–488 (2009).
VandenDriessche, T., Collen, D. & Chuah, M. K. Gene therapy for the hemophilias. J. Thromb. Haemost. 1, 1550–1558 (2003).
Cattaneo, R., Miest, T., Shashkova, E. V. & Barry, M. A. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nature Rev. Microbiol. 6, 529–540 (2008).
Modlich, U. & Baum, C. : Preventing and exploiting the oncogenic potential of integrating gene vectors. J. Clin. Invest. 119, 755–758 (2009).
High, K. A. Gene therapy: the moving finger. Nature 435, 577–579 (2005).
European Medicines Agency. Scientific guidelines for human medicinal products —multidisciplinary guidelines — gene therapy. EMA web site [online], (2010).
The European Parliament and the Council of the European Union. Council Directive of 20 June 1990 on the approximation of the laws of the Member States relating to active implantable medical devices (90/385/EEC). Official J. Eur. Union 11.10.2007, 003.001/1–003.001/35 (2007).
The European Parliament and the Council of the European Union. Council Directive 93/42/EEC of 14 June 1993 concerning medical devices. Official J. Eur. Union 12.7.1993, 1–43 (1993).
European Medicines Agency. Committee for Advanced Therapies (CAT): Procedural Advice on the provision of scientific recommendation on classification of advanced therapy medicinal products in accordance with Article 17 of Regulation (EC) No 1394/2007. EMEA/99623/2009. EMA web site [online], (2007).
European Medicines Agency. Committee for Orphan Medicinal Products (COMP). EMA web site [online], (2010).
European Medicines Agency. Committee for Advanced Therapies (CAT): Procedural Advice on the evaluation of advanced therapy medicinal products in accordance with Article 8 of Regulation (EC) No 1394/2007. EMEA/630043/2008. EMA web site [online], (2009).
European Medicines Agency. Press Release — European Medicines Agency recommends first marketing authorisation for an advanced therapy medicinal product. EMEA/CHMP/394741/2009. EMA web site [online], (2009).
The CAT Chairman wishes to thank those CAT colleagues who took as 'Rapporteurs' the lead in the discussions of the subsections of this article to coordinate the participation of the entire Committee, namely: P. Salmikangas (CAT Vice-Chair and Finnish CAT member) and A. Tsiftsoglou (Greek CAT member) for CBMPs; T. VandenDriessche (Alternate for Clinicians' Representative) for the gene therapy section; W. Cheng (Swedish CAT Alternate) for the section on combined ATMPs; and P. Celis (EMA CAT Scientific Secretariat) for the section on how the CAT is involved in the development of ATMPs.
For details of competing financial interests for each member please see the Committee for Advanced Therapeutics website (http://www.ema.europa.eu/htms/general/contacts/CAT/CAT_members.html).
About this article
Cite this article
The Committee for Advanced Therapies (CAT). Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov 9, 195–201 (2010). https://doi.org/10.1038/nrd3052
Dendritic cell-based vaccine prolongs survival and time to next therapy independently of the vaccine cell number
Biology Direct (2022)
Towards the standardization of methods of tissue processing for the isolation of mesenchymal stromal cells for clinical use
Stem Cell Research & Therapy (2020)
Journal of Translational Medicine (2018)
Scientific Reports (2018)